Caris Life Sciences (CAI) EBITDA (2024 - 2026)

Caris Life Sciences' EBITDA history runs 3 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• On a quarterly basis, EBITDA rose 109.11% year-over-year to $5.3 million in Q1 2026; TTM through Mar 2026 was $108.3 million, a 148.62% increase from a year earlier, with the FY2025 full-year figure at $45.1 million, up 117.55% from the prior year.
• EBITDA fell to $5.3 million in Q1 2026 per CAI's latest filing, from $88.4 million in the prior quarter.
• Across five years, EBITDA topped out at $88.4 million in Q4 2025 and bottomed at -$67.0 million in Q2 2024.
• The 3-year median for EBITDA is -$27.5 million (2024), against an average of -$14.3 million.
• Biggest YoY gain for EBITDA was 338.65% in 2025; the steepest drop was 73.16% in 2025.
• Year by year, EBITDA stood at -$37.0 million in 2024, then soared by 338.65% to $88.4 million in 2025, then tumbled by 94.03% to $5.3 million in 2026.
• Per Business Quant, the three latest CAI EBITDA figures stand at $5.3 million (Q1 2026), $88.4 million (Q4 2025), and $32.6 million (Q3 2025).